Anthony Whetton

Dr. Anthony Whetton

orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
SWSteven L. Wood
Steven L. Wood
MPMaria Pernemalm
Maria Pernemalm
PCPhil Crosbie
Phil Crosbie
AWAnthony Whetton
Anthony Whetton

10 January 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
NANaomi E. Allen
Naomi E. Allen
BLBen Lacey
Ben Lacey
DLDeborah A. Lawlor
Deborah A. Lawlor
JPJill P. Pell
Jill P. Pell
JGJohn Gallacher
John Gallacher
RCRory Collins
Rory Collins
Population-based prospective studies, such as UK Biobank, are valuable for generating and testing hypotheses about the potential causes of human disease. We describe how UK Biobank’s study design, data access policies, and approaches to statistical analysis can help to minimize error and improve the interpretability of research findings, with implications for other population-based prospective studies being established worldwide.

19 November 2009 in Nature
Verified
Journal Article
Open access
PDF file
RLRong Lu
Rong Lu
FMFlorian Markowetz
Florian Markowetz
RURichard Unwin
Richard Unwin
JLJeffrey T. Leek
Jeffrey T. Leek
EAEdoardo M. Airoldi
Edoardo M. Airoldi
ILIhor R. Lemischka
Ihor R. Lemischka
Rong Lu et al. present a dynamic systems-level study of cell fate changes in mouse embryonic stem cells following a single well-defined perturbation by downregulating the pluripotency factor Nanog. They measure global changes in histone acetylation, chromatin-bound RNA polymerase II, mRNA and nuclear protein levels for five days, and find progressive widespread changes in multiple molecular regulatory layers and provide a dynamic view of information flow in the epigenome, transcriptome and proteome. The interaction between the different molecular mechanisms that regulate changes in embryonic stem cell (ESC) fate is not fully understood. A dynamic systems-level study of cell fate change in murine ESCs following a well-defined perturbation is now presented; the data demonstrate how a single genetic perturbation leads to widespread changes in several molecular regulatory layers, and provide a dynamic view of information flow in the epigenome, transcriptome and proteome. Molecular regulation of embryonic stem cell (ESC) fate involves a coordinated interaction between epigenetic1,2,3,4, transcriptional5,6,7,8,9,10 and translational11,12 mechanisms. It is unclear how these different molecular regulatory mechanisms interact to regulate changes in stem cell fate. Here we present a dynamic systems-level study of cell fate change in murine ESCs following a well-defined perturbation. Global changes in histone acetylation, chromatin-bound RNA polymerase II, messenger RNA (mRNA), and nuclear protein levels were measured over 5 days after downregulation of Nanog, a key pluripotency regulator13,14,15. Our data demonstrate how a single genetic perturbation leads to progressive widespread changes in several molecular regulatory layers, and provide a dynamic view of information flow in the epigenome, transcriptome and proteome. We observe that a large proportion of changes in nuclear protein levels are not accompanied by concordant changes in the expression of corresponding mRNAs, indicating important roles for translational and post-translational regulation of ESC fate. Gene-ontology analysis across different molecular layers indicates that although chromatin reconfiguration is important for altering cell fate, it is preceded by transcription-factor-mediated regulatory events. The temporal order of gene expression alterations shows the order of the regulatory network reconfiguration and offers further insight into the gene regulatory network. Our studies extend the conventional systems biology approach to include many molecular species, regulatory layers and temporal series, and underscore the complexity of the multilayer regulatory mechanisms responsible for changes in protein expression that determine stem cell fate.

26 August 2010 in Nature Protocols
Verified
Journal Article
Closed access
RURichard Unwin
Richard Unwin
JGJohn R Griffiths
John R Griffiths
AWAnthony Whetton
Anthony Whetton

1 May 2008 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
APAndrew Pierce
Andrew Pierce
RURichard Unwin
Richard Unwin
CECaroline A. Evans
Caroline A. Evans
SGStephen Griffiths
Stephen Griffiths
LCLouise Carney
Louise Carney
AWAnthony Whetton
Anthony Whetton
There are a number of leukemogenic protein-tyrosine kinases (PTKs) associated with leukemic transformation. Although each is linked with a specific disease their functional activity poses the question whether they have a degree of commonality in their effects upon target cells. Exon array analysis of the effects of six leukemogenic PTKs (BCR/ABL, TEL/PDGFRβ, FIP1/PDGFRα, D816V KIT, NPM/ALK, and FLT3ITD) revealed few common effects on the transcriptome. It is apparent, however, that proteome changes are not directly governed by transcriptome changes. Therefore, we assessed and used a new generation of iTRAQ tagging, enabling eight-channel relative quantification discovery proteomics, to analyze the effects of these six leukemogenic PTKs. Again these were found to have disparate effects on the proteome with few common targets. BCR/ABL had the greatest effect on the proteome and had more effects in common with FIP1/PDGFRα. The proteomic effects of the four type III receptor kinases were relatively remotely related. The only protein commonly affected was eosinophil-associated ribonuclease 7. Five of six PTKs affected the motility-related proteins CAPG and vimentin, although this did not correspond to changes in motility. However, correlation of the proteomics data with that from the exon microarray not only showed poor levels of correlation between transcript and protein levels but also revealed alternative patterns of regulation of the CAPG protein by different oncogenes, illustrating the utility of such a combined approach.

8 June 2016 in Nature
Verified
Journal Article
Open access
PDF file
SASheela A. Abraham
Sheela A. Abraham
LHLisa E. M. Hopcroft
Lisa E. M. Hopcroft
ECEmma Carrick
Emma Carrick
MDMark E. Drotar
Mark E. Drotar
KDKaren Dunn
Karen Dunn
THTessa L. Holyoake
Tessa L. Holyoake
Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR–ABL. Direct inhibition of BCR–ABL kinase has revolutionized disease management, but fails to eradicate leukaemic stem cells (LSCs), which maintain CML. LSCs are independent of BCR–ABL for survival, providing a rationale for identifying and targeting kinase-independent pathways. Here we show—using proteomics, transcriptomics and network analyses—that in human LSCs, aberrantly expressed proteins, in both imatinib-responder and non-responder patients, are modulated in concert with p53 (also known as TP53) and c-MYC regulation. Perturbation of both p53 and c-MYC, and not BCR–ABL itself, leads to synergistic cell kill, differentiation, and near elimination of transplantable human LSCs in mice, while sparing normal HSCs. This unbiased systems approach targeting connected nodes exemplifies a novel precision medicine strategy providing evidence that LSCs can be eradicated.